The FDA approved Roivant’s dermatomyositis drug brepocitinib for the treatment of dermatomyositis, with the pill marketed as Lisraya. The approval provides an initial major regulatory validation for Roivant and its subsidiary Priovant and creates a new oral option to replace or reduce reliance on high-dose steroids and other immune-suppressing regimens. The decision also sets up competitive dynamics for oral small-molecule immune therapies in rare autoimmune disease, with an approval focused on the patient population that historically depended on complex immunosuppression.